化疗所致血小板减少症治疗的研究进展

Treatment progress of chemotherapy induced thrombocytopenia

化疗所致血小板减少症（Chemotherapy—inducedthronlbocytopenia，CIT）是常见的化疗药物剂量限制性毒性反应，可能导致化疗药物剂量降低或化疗时间延迟，甚至可能导致出血事件发生。输注血小板是治疗CIT的基本方法。促血小板生长因子的出现，如重组人白介素-11（Recombinanthumanin．terleukin-11，rhIL-11）、重组人血小板生成素（Recombinanthumanthrombopoietin，rhTPO）和m小板生成素受体激动剂（Thrombopoietinreceptoragonist，TPO—RA），为我们提供了方便有效的治疗策略。其它一些因子和近端脾动脉栓塞术（Proximalsplenicarteryembolization，PSAE）有可能成为新的治疗药物或方法。本文就CIT治疗的研究进展进行综述。

Chemotherapy induced thrombocytopenia（CIT）is a major dose -limiting hematologic toxicity with cancer patients. Aside from bleeding risk, thrombocytopenia limits chemotherapy doses and frequencies. While platelet transfusion is remain the elementary method for CIT, administration of platelet growth factors, such as recombinant human interleukin - 11 （rhlL - 11 ）, recombinant human thrombopoietin （rhTPO）and thrombopoietin receptor agonist （ TPO - RA ）, are convenient and effective platelet - support strategies for patients receiving myelosuppressive chemotherapy. In addition, other cytokines and proximal splenic artery embolization （PSAE）are expected to be new clinical therapies. In this review, we summarize the existing data and approaches in the treat- ment progress of CIT.